Clinical Trials Browser

Phase 2 × Lymphoma × siplizumab × Clear all

NCT00113646 2018-03-16

Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies

Phase 2 Terminated

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes